We Use Gene Editing to Eliminate Immune System Damages in Autoimmune and Chronic Diseases 

Give me a lever and a place to stand
and I will move the world
~Archimedes

Asset 35.png

WE ARE LEMPO AND WE USE CRISPR TO MOVE THE WORLD

Our core product MP-001 is a CRISPR based treatment for removing the Myeloperoxidase (MPO) gene in CD34+ stem cells. 

It eliminates the autoantigen in several autoimmune diseases and dramatically reduces the damages caused by excessive activation of the immune system in other diseases.

Development of MP-001 is done and we are now in pre-clinical stage with two lead rare, life threatening indications:

MPO-ANCA associated Glomerulonephritis (AAGN)
and
Pulmonary Arterial Hypertension (PAH)

Once we commence the first clinical trial and assure safety of MP-001, we will be able to expand our pipeline to many indications without requiring any changes to the product itself and while relying on the same regulatory framework and manufacturing operation.
This is a Pipeline in a Product

Evidence (in animal models) for the therapeutic value of MPO suppression in the following list of diseases: Alzheimer’s Disease, Multiple Sclerosis, Parkinson’s Disease, Atherosclerosis, Chronic Obstructive Pulmonary Disease, Cytarabine resistant Acute Myeloid Leukemia, Lung cancer, Prevention of Metastasis, Kidney transplant ABMR and more

Asset 18.png

A life mission, Not a venture

Diagnosed with Multiple Sclerosis (MS) and confined to a wheelchair because of it, Oren Glanz, CEO took interest in new therapies to treat diseases like his. One day he was approached by his friend, Dr. Anat Kahana, that worked with Prof. Ben-Zion Garty on MPO and its role in diseases including MS. This was the beginning of the journey of Lempo which was established in 2017.

Once approved by the regulation Oren plans to make use of MP-001 hoping to be able to walk again.